Journal
PROTEIN & CELL
Volume 9, Issue 6, Pages 516-526Publisher
OXFORD UNIV PRESS
DOI: 10.1007/s13238-017-0394-6
Keywords
cancer stem cells; chimeric antigen receptor; immunotherapy; translational medicine; response evaluation criterion
Categories
Funding
- National Natural Science Foundation of China [81230061]
- Science and Technology Planning Project of Beijing City [Z151100003915076]
- National Key Research and Development Program of China [2016YFC1303501, 2016YFC1303504]
- Nursery Innovation Fund [15KMM50]
Ask authors/readers for more resources
Cancer stem cells (CSCs), a subpopulation of tumor cells, have self-renewal and multi-lineage differentiation abilities that play an important role in cancer initiation, maintenance, and metastasis. An accumulation of evidence indicates that CSCs can cause conventional therapy failure and cancer recurrence because of their treatment resistance and self-regeneration characteristics. Therefore, approaches that specifically and efficiently eliminate CSCs to achieve a durable clinical response are urgently needed. Currently, treatments with chimeric antigen receptor-modified T (CART) cells have shown successful clinical outcomes in patients with hematologic malignancies, and their safety and feasibility in solid tumors was confirmed. In this review, we will discuss in detail the possibility that CART cells inhibit CSCs by specifically targeting their cell surface markers, which will ultimately improve the clinical response for patients with various types of cancer. A number of viewpoints were summarized to promote the application of CSC-targeted CART cells in clinical cancer treatment. This review covers the key aspects of CSC-targeted CART cells against cancers in accordance with the premise of the model, from bench to bedside and back to bench.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available